Thr517

Site Information
GFGKKtWtFCGtPEY SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 452153
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ) , mutation of modification site ( 13 )
Disease tissue studied:	liver cancer, surrounding tissue ( 8 ) , lung cancer ( 1 , 2 , 6 , 7 , 9 , 10 , 12 ) , non-small cell lung cancer ( 2 , 6 , 7 , 9 ) , non-small cell lung cancer, surrounding tissue ( 11 ) , non-small cell lung adenocarcinoma ( 1 , 2 ) , non-small cell squamous cell lung carcinoma ( 1 ) , melanoma skin cancer ( 4 , 5 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 3 ) , Cal-12T (pulmonary) ( 2 ) , HCC15 (pulmonary) ( 1 ) , HCC44 (pulmonary) ( 2 ) , HEK293T (epithelial) ( 13 ) , liver ( 8 ) , LOU-NH91 (squamous) ( 1 ) , lung ( 1 , 2 , 6 , 7 , 9 , 10 , 11 , 12 ) , NCI-H1437 (pulmonary) ( 2 ) , NCI-H1666 (pulmonary) ( 2 ) , NCI-H1703 (squamous) ( 1 ) , NCI-H2073 (pulmonary) ( 1 ) , NCI-H2342 (pulmonary) ( 1 ) , NCI-H2405 (pulmonary) ( 2 ) , skin ( 4 , 5 )

Downstream Regulation
Effects of modification on PKG1:	enzymatic activity, induced ( 13 ) , phosphorylation ( 13 )
Effects of modification on biological processes:	transcription, altered ( 13 )

References
1	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
2	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
3	Guo A (2010) CST Curation Set: 6258; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631 Curated Info
4	Tucker M (2010) CST Curation Set: 9779; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
5	Tucker M (2010) CST Curation Set: 9783; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
6	Rikova K (2010) CST Curation Set: 9470; Year: 2010; Biosample/Treatment: tissue, /untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
7	Rikova K (2010) CST Curation Set: 9471; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
8	Tucker M (2010) CST Curation Set: 8909; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
9	Rikova K (2009) CST Curation Set: 8541; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
10	Rikova K (2009) CST Curation Set: 8549; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
11	Rikova K (2009) CST Curation Set: 8539; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
12	Rikova K (2008) CST Curation Set: 4102; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631 Curated Info
13	Browning DD, McShane MP, Marty C, Ye RD (2000) Nitric oxide activation of p38 mitogen-activated protein kinase in 293T fibroblasts requires cGMP-dependent protein kinase. J Biol Chem 275, 2811-6 10644746 Curated Info